Bluebird Bio (Group)

https://www.bluebirdbio.com

With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and cancer. bluebird bio’s gene therapy clinical programs include its Lenti-D™ product candidate, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin™ BB305 product candidate, currently in three clinical studies for the treatment of transfusion-dependent ß-thalassemia, and severe sickle cell disease. bluebird bio’s oncology pipeline is built upon the company’s leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird bio’s lead oncology program, bb2121, is an anti-BCMA CAR T program partnered with Celgene. bb2121 is currently being studied in a Phase 1 trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies with the potential for use across the company’s pipeline. *

	Start	2014-06-16 existent
	Industry	gene therapy
	Industry 2	genome editing (gene editing)
	Person	Leschly, Nick (Bluebird Bio 201606 CEO)

	Region	Cambridge, MA
	Country	United States (USA)
	Street	150 2nd Street
	City	02141 Cambridge, MA
	Tel	+1-339-499-9300
		Address record changed: 2024-01-05

Basic data	Employees	D: 101 to 500 (2023-01-31)
	Currency	USD
	Annual sales	3,597,000 (revenues, total, consolidated (2022) 2022-12-31)
	Profit	-266,578,000 (2022-12-31)
	Cash	113,006,000 (2022-12-31)

		* Document for »About Section«:

		Record changed: 2024-06-07